Thursday, July 9, 2026

pharma · Osteoarthritis, Knee · Eosinophilic esophagitis · EPRX

EUPRAXIA PHARMACEUTICALS

EUPRAXIA PHARMACEUTICALS is a pharma organization headquartered in Victoria, CA. It trades on NYSE under ticker EPRX. Primary therapeutic focus areas include Osteoarthritis, Knee, Eosinophilic esophagitis, Eosinophilic E

Victoria, CA HQ
2012 Founded
52 Employees
Public company Type
EPRX · NYSE Ticker
Company details
Status
Public
HQ
Victoria, CA
Founded
2012
Employees
52
Programs
4
Drugs
1
Patents
3
Clinical program

EP-104GI

Phase 2 · small molecule · Eosinophilic Esophagitis

EP-104GI for Eosinophilic Esophagitis is a Phase 2 program (small_molecule) at EUPRAXIA PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).

Internal code EP-104IAR-102 (RESOLVE)

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
EUPRAXIA PHARMACEUTICALS INC.
Phase
Phase 2
Modality
small_molecule
Indication
Eosinophilic Esophagitis
Status
active
Trials
1

Clinical trials